Simonian Nancy A 4

What Happened

• Nancy A. Simonian, a director of Generate Biomedicines, was granted a derivative award on 2026-02-26 to acquire 29,561 shares. The reported acquisition price is $0.00 (a grant of options/award), so no cash was paid at grant. The filing classifies the transaction as a derivative award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (filed within the typical two-business-day window).
• Amount: 29,561 shares (derivative award); reported price: $0.00.
• Vesting: Footnote F1 — the shares underlying this option vest in full on February 19, 2027, subject to the reporting person’s continued service on that date.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No immediate sale or cashless exercise reported — this is a grant/award, not a disposition.

Context

• This was an option/award grant intended as compensation or retention — it is not the same signal as an outright purchase by the insider. The award will only convert into actual shares if/when it vests and is exercised according to plan terms.